AMOYTOP(SH:688278) Sou Hu Cai Jing·2025-09-11 06:01Core Viewpoint - The company has achieved significant breakthroughs in the biopharmaceutical sector during the "14th Five-Year Plan" period, emphasizing that continuous innovation is essential for survival and development [2][3]. Group 1: Achievements and Innovations - The company has supported the China Hepatitis Prevention Foundation's Everest Project, helping over 10,000 hepatitis B patients achieve clinical cure, with a surface antigen clearance rate exceeding 30% after 48 weeks of treatment, compared to the previous 1% to 3% [3][9]. - The company has made substantial progress in scientific research and new drug development, with multiple breakthroughs in the "14th Five-Year Plan" period, including the launch of a national Class 1 new drug in 2023 and another in 2025 [7][10]. - The company has six protein-based biopharmaceuticals approved for market and several Class 1 new drugs in clinical research, covering long-acting proteins, nucleic acid drugs, and gene therapy [10]. Group 2: Financial Growth and Market Position - The company's revenue and net profit for 2024 are projected to be 28.17 billion and 8.28 billion respectively, representing 3.86 times and 12.87 times the figures from 2019 [14]. - The company raised a net amount of 330 million through its listing on the Sci-Tech Innovation Board, which has alleviated previous funding constraints for clinical development [12][14]. Group 3: Future Outlook - The company is optimistic about the next 5 to 10 years, expecting to showcase the results of its past efforts with more new technologies and products [15]. - The company aims to transition from a product and technology-centric organization to one that utilizes multiple platforms and tools to address disease issues [18]. - The company is focusing on expanding its global presence, recognizing the increasing demand for biopharmaceuticals both domestically and internationally [19].